[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"helicobacter-pylori-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:helicobacter-pylori-infection":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,47,0,25,[9,41,65,93,115,137,167,191,218,249,272,293,317,343,367,387,408,429,452,476,498,523,545,571,591],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100497880","application-of-artificial-intelligence-on-the-diagnosis-of-helicobacter-pylori-infection-and-premalignant-gastric-lesion-100497880",false,"NCT05762991","Application of Artificial Intelligence on the Diagnosis of Helicobacter Pylori Infection and Premalignant Gastric Lesion","Application of Artificial Intelligence on the Diagnosis of Helicobacter Pylori Infection and Premalignant Gastric Lesion: A Randomized Clinical Trial","Inclusion Criteria:\n\n1. Age 20-80\n2. Scheduled endoscopy\n\nExclusion Criteria:\n\n1\\. History of gastric surgery","ALL","20 Years","80 Years",{"count":21,"type":22},6000,"ESTIMATED","OBSERVATIONAL","The aim of this study is to evaluate the impact of artificial intelligence (AI) assistance during routine upper endoscopy on gastric cancer-specific mortality. We hypothesize that AI-assisted endoscopic interpretation can further reduce gastric cancer-related mortality through two mechanisms: (1) improved detection of H. pylori infection, facilitating timely eradication therapy and subsequent prevention of gastric carcinogenesis; and (2) earlier identification of premalignant gastric conditions, enabling appropriate surveillance endoscopy and earlier detection of gastric cancer. The primary endpoint is gastric cancer-specific mortality.",[26,27],"Helicobacter Pylori Infection","Premalignant Lesion","RECRUITING","2026-06-21",{"date":31,"type":32},"2026-06-24","ACTUAL",{"date":34,"type":32},"2021-12-24",{"date":36,"type":22},"2028-12-31",{"name":38,"class":39},"National Taiwan University Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":19,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":50,"conditions":51,"keywords":52,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100632636","effect-of-ppis-on-stool-dna-test-for-h-pylori-100632636","NCT07516262","Effect of PPIs on Stool DNA Test for H. Pylori","Effect of Proton Pump Inhibitors on Stool DNA Detection of Helicobacter Pylori: A Prospective Clinical Study","Inclusion Criteria:\n\n* Male or female patients aged 18-80 years;\n* No prior H. pylori eradication therapy;\n* Patients requiring proton pump inhibitor (PPI) therapy in the near future due to gastritis, peptic ulcer disease, or other indicated conditions;\n* Patients with at least two positive results among H. pylori antibody test, histology, and rapid urease test (RUT);\n* Provision of signed informed consent and being informed of the specific study protocol.\n\nExclusion Criteria:\n\n* Prior H. pylori eradication therapy;\n* Pregnant or lactating women;\n* Acute gastrointestinal bleeding;\n* History of subtotal gastrectomy;\n* Severe dysfunction of vital organs (heart, liver, kidney, lungs, etc.) or congenital diseases, such as class IV cardiac insufficiency, liver failure, uremia, respiratory failure, hemophilia, Wilson's disease, etc.;\n* Refusal of enrollment by the guardian or the patient;\n* Alcohol and\u002For drug abuse (addiction or dependence), or poor compliance as judged by the investigator;\n* Individuals without legal capacity or with impaired insight;\n* Abnormal neurological signs on physical examination;\n* Use of oral antibiotics with bactericidal activity against H. pylori within 4 weeks.","18 Years",{"count":7,"type":22},"This prospective, self-controlled clinical study aims to evaluate the impact of proton pump inhibitor (PPI) use on the accuracy of stool DNA testing for Helicobacter pylori (H. pylori) and to assess the applicability of this test in patients receiving PPI therapy. Patients requiring long-term PPI treatment and meeting the inclusion criteria were enrolled. After at least four weeks of PPI therapy, a stool DNA test was performed, along with collection of gastric mucosal samples via gastroscopy for tissue PCR, histology, and rapid urease testing, as well as H. pylori antibody detection. Subsequently, PPI treatment was discontinued for four weeks, after which a 13C-urea breath test and a repeat stool DNA test were conducted. By comparing the sensitivity, specificity, and consistency of stool DNA testing before and after PPI discontinuation, this study aims to characterize the interference of PPIs with the test results, thereby providing evidence to support improvements in H. pylori diagnostic methods.",[26],[53,54,55],"Helicobacter pylori","Stool DNA Testing","Proton pump inhibitors","2026-06-04",{"date":58,"type":32},"2026-06-05",{"date":60,"type":32},"2025-05-01",{"date":62,"type":22},"2026-06-30",{"name":64,"class":39},"Shanghai Jiao Tong University School of Medicine",{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":19,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":40},"100637972","phase-4-vonoprazan-high-dose-dual-vs-levofloxacin-concomitant-100637972","NCT07624422","Vonoprazan High-Dose Dual VS Levofloxacin Concomitant","Efficacy and Safety of Vonoprazan High-Dose Dual Therapy Compared to Levofloxacin Concomitant Therapy for H. Pylori Eradication: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 80 years (adjust upper limit as needed)\n* Confirmed Helicobacter pylori infection by at least one of the following: positive urea breath test, rapid urease test, histopathology, or stool antigen test\n* Treatment-naïve for H. pylori (no prior eradication therapy) - OR - prior treatment failure (specify if rescue therapy)\n* Willing and able to provide written informed consent\n* Willing to adhere to the 14-day treatment regimen and follow-up visits\n* For women of childbearing potential: negative pregnancy test and agreement to use effective contraception during the treatment period\n\nExclusion Criteria:\n\n* History of allergy or hypersensitivity to vonoprazan, amoxicillin, clarithromycin, metronidazole, or any other penicillin\u002Fcephalosporin\n* Previous H. pylori eradication therapy (if study is for first-line treatment)\n* Active gastrointestinal bleeding or perforation\n* Severe liver disease (Child-Pugh class B or C) or severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²)\n* Pregnancy or breastfeeding\n* Concurrent use of medications with significant drug-drug interactions (e.g., warfarin, phenytoin, digoxin, atazanavir, rilpivirine)\n* Malignancy or any life-threatening condition with life expectancy \\\u003C 6 months\n* Participation in another interventional trial within 30 days prior to enrollment\n* Any condition that, in the investigator's opinion, precludes safe participation or adherence to the protocol",{"count":73,"type":22},150,"INTERVENTIONAL",[76],"PHASE4","This is a randomized controlled trial comparing the efficacy and safety of two vonoprazan-based regimens: high-dose dual therapy (vonoprazan plus a single antibiotic) versus triple therapy (vonoprazan plus two antibiotics) for the treatment of H. pylori infection).\n\nParticipants will be randomly assigned to receive either regimen for 14 days. The primary outcome is eradication rate , and secondary outcomes include adverse events and treatment adherence.",[26,79,80],"Peptic Ulcer Disease","Gastritis",[26,82],"Vonoprazan","NOT_YET_RECRUITING","2026-06-01",{"date":86,"type":32},"2026-06-03",{"date":88,"type":22},"2026-11-01",{"date":90,"type":22},"2027-12-31",{"name":92,"class":39},"Damascus Hospital",{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":74,"phases":103,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":113,"locationsCount":40},"100626731","simplified-dual-regimen-guided-by-fecal-clarithromycin-resistance-gene-detection-for-first-line-h-pylori-eradication-100626731","NCT07439445","Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication","Efficacy and Safety of Simplified Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line Helicobacter Pylori Eradication","Inclusion Criteria:\n\n1. Aged 18-70 years;\n2. Positive results for both ¹³C-urea breath test (¹³C-UBT) and fecal polymerase chain reaction (PCR), confirming Helicobacter pylori infection, with a clinical indication for H. pylori eradication as judged by the physician;\n3. Treatment-naïve individuals with no prior history of H. pylori eradication therapy.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. Patients with a history of allergy to any drugs used in the eradication regimen\n3. Patients with severe systemic diseases or malignant tumors\n4. History of gastric resection surgery\n5. Recent use of antibiotics or bismuth salts (within 4 weeks), H₂-receptor antagonists, proton pump inhibitors (PPIs), or Potassium-competitive acid blockers(P-CABs) (within 2 weeks).","70 Years",{"count":102,"type":22},70,[104],"NA","To investigate the efficacy, safety, and compliance of a simplified strategy using vonoprazan plus clarithromycin for first-line treatment in patients with Helicobacter pylori infection, among those infected with strains without clarithromycin resistance gene mutations based on fecal clarithromycin resistance gene detection.",[26],"2026-04-25",{"date":109,"type":32},"2026-04-30",{"date":107,"type":32},{"date":112,"type":22},"2027-02-13",{"name":114,"class":39},"Peking University First Hospital",{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":122,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":74,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":40},"100545483","tegoprazan-containing-sequential-for-h-pylori-100545483","NCT06382493","Tegoprazan-containing Sequential for H. Pylori","Efficacy of Tegoprazan-containing Sequential Therapy Compared to Proton Pump Inhibitor-based Eradication in South Korea, a Region With High Antimicrobial Resistance: A Prospective Randomized Single Tertiary Center Study","Inclusion Criteria:\n\nPatients who had H. pylori infection proved by positive test result of urea breath test (UBT), rapid urase test or pathologic examination (warthin-giemsa staining)\n\nExclusion Criteria:\n\n* congestive heart failure, NYHA III or IV\n* end-stage renal disease\n* alcoholics\n* drug abusers\n* pregnant or nursing women",true,{"count":124,"type":22},400,[104],"As H. pylori eradication, the investigators prepared a randomized controlled clinical trial whether tegoprazan-containing 10-day sequential treatment was effective compared to conventional PPI-containing 10-day sequential eradication therapy",[26],"2026-04-23",{"date":130,"type":32},"2026-04-28",{"date":132,"type":32},"2021-02-01",{"date":134,"type":22},"2026-12-12",{"name":136,"class":39},"Seoul National University Bundang Hospital",{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":74,"phases":146,"briefSummary":147,"conditions":148,"keywords":152,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},"100634280","phase-4-vonoprazan-based-versus-esomeprazole-based-triple-therapy-for-helicobacter-pylori-eradication-100634280","NCT07537634","Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication","Comparison Between Vonoprazan-Based Triple Therapy and Esomeprazole-Based Triple Therapy for Eradication of Helicobacter Pylori Infection: An Open-Label Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Dyspeptic patients with positive for both rapid urease test and stool antigen test\n3. Patients giving written informed consent\n\nExclusion Criteria:\n\n1. Treatment with a proton pump inhibitor, H2-receptor antagonist within the last 2 weeks, prior to the study\n2. Treatment with antibiotics or bismuth preparation within 4 weeks prior to the study\n3. Previous H. pylori eradication therapy\n4. Gastric or duodenal ulcer with current or recent bleeding on endoscopy\n5. Significant upper or lower gastrointestinal bleeding within 4 weeks\n6. Patients with regular intake of NSAIDs or steroids\n7. Surgery that might affect gastric acid secretion e.g., upper GI resection or vagotomy\n8. Known case of malignancy, including MALToma\n9. Advanced co-morbidities (e.g., CLD, CKD, cardio-respiratory failure, known thyroid disease)\n10. Chronic alcohol abuse, chronic illegal drug use, or drug addiction within the past 12 months\n11. Pregnant, lactating woman or intend to become pregnant within the study period\n12. History of hypersensitivity to vonoprazan, PPIs, amoxicillin, and\u002For levofloxacin\n13. On colchicine\n14. Subjects with abnormal laboratory test at the start of the screening period:\n\nS. creatinine \\> 2 mg\u002Fdl SGPT \\> 2 x Upper limit of normal",{"count":145,"type":22},80,[76],"The goal of this clinical trial is to compare the efficacy and safety of vonoprazan-based levofloxacin-containing triple therapy with esomeprazole-based levofloxacin-containing triple therapy for eradication of Helicobacter pylori infection in adults with dyspepsia.\n\nThe main questions it aims to answer are whether vonoprazan-based triple therapy achieves a higher eradication rate of H. pylori, whether it provides greater improvement in dyspeptic symptoms, and what adverse effects are associated with each regimen.\n\nResearchers will compare the two treatment regimens to determine which is more effective for H. pylori eradication.\n\nParticipants with confirmed H. pylori infection will be randomly assigned to receive either vonoprazan-based or esomeprazole-based triple therapy for 14 days.\n\nFour weeks after completion of therapy, participants will undergo repeat stool antigen testing to assess eradication.\n\nDrug compliance, adverse effects, and dyspeptic symptom scores will be recorded during follow-up.\n\nParticipants with endoscopic mucosal lesions at baseline will undergo follow-up endoscopy for reassessment.",[26,149,79,150,151],"Dyspepsia","Helicobacter Pylori","H Pylori",[53,153,82,154,155,156,149],"Helicobacter pylori eradication","Esomeprazole","Levofloxacin","Triple therapy","2026-04-18",{"date":159,"type":32},"2026-04-22",{"date":161,"type":22},"2026-04-15",{"date":163,"type":22},"2026-08-14",{"name":165,"class":39},"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",2,{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":74,"phases":176,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":40},"100464803","phase-4-efficacies-of-susceptibility-guided-vs-empiric-therapy-for-rescue-treatment-of-helicobacter-pylori-infection-100464803","NCT05332444","Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection - A Prospective Randomized, Comparative Study","Inclusion Criteria:\n\nPatients, aged \\>= 20, having H. pylori-positive chronic gastritis with\u002Fwithout peptic ulcers (duodenal or gastric ulcers) will be recruited. If the patients failed anti-H. pylori therapy previously, they will be invited to enter this study for evaluating the efficacy of these rescue regimens.\n\nExclusion Criteria:\n\n1. pregnant or nursing woman;\n2. serious concomitant illness and malignant tumor of any kind;\n3. history of hypersensitivity to test drugs；\n4. serious bleeding during the course of this ulcer;\n5. previous gastric surgery;\n6. receiving bismuth salts, PPIs, or antibiotics in the previous month.",{"count":175,"type":22},450,[76],"The prevalence of H. pylori antibiotic resistance has reached an alarming level worldwide. Antibiotic stewardship programs should be urgently developed and implemented. However, H. pylori antimicrobial susceptibility testing (AST) is rarely offered, making local resistance patterns not easily available. Guideline-recommended empiric therapies (GR-ET) may no longer reliably achieve high cure rate in the era of increasing antibiotic resistance. susceptibility-guided tailored therapy (SG-TT) may be a good choice to solve this problem.\n\nThe aims of this study are:\n\n1. to compare the efficacy of SG-TT with GR-ET as rescue regimens for H. pylori eradication;\n2. to compare the patient adherence and adverse effects of these treatment regimens;\n3. to investigate factors that may influence H. pylori eradication by these treatment regimens.",[26],[53,180,181,182,183],"antimicrobial susceptibility testing","minimal inhibitory concentration","susceptibility-guided tailored therapy","guideline-recommended empiric therapy","2026-04-12",{"date":161,"type":32},{"date":187,"type":32},"2022-04-11",{"date":189,"type":22},"2026-12",{"name":38,"class":39},{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":200,"conditions":201,"keywords":204,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":4},"100628196","predicting-peptic-complications-using-h-pylori-serology-and-gastric-ultrasound-100628196","NCT07458490","Predicting Peptic Complications Using H. Pylori Serology and Gastric Ultrasound","H. Pylori Serology and Gastric Ultrasound Findings in Predicting Peptic Complications","Inclusion Criteria:\n\n* Adult patients (age ≥18 years) presenting with dyspeptic symptoms (epigastric pain, nausea, vomiting, heartburn).\n* Patients with suspected or confirmed peptic ulcer disease.\n* Patients presenting with acute complications (hematemesis, melena, acute - abdominal pain suggestive of perforation).\n* Patients with history of peptic ulcer disease requiring surveillance.\n* Patients who provide informed consent.\n\nExclusion Criteria:\n\n* Previous gastric surgery (gastrectomy, vagotomy).\n* Active malignancy (gastric cancer, lymphoma).\n* Previous H. pylori eradication therapy within 4 weeks.\n* Current use of proton pump inhibitors (PPIs) within 2 weeks (may affect antibody levels and ultrasound findings).\n* Severe coagulopathy or bleeding disorders (INR \\>2.0).\n* Pregnancy.\n* Poor quality ultrasound images due to excessive bowel gas or obesity.\n* Hemodynamically unstable patients requiring immediate intervention.\n* Refusal to participate in the study.",{"count":199,"type":22},230,"This observational study aims to evaluate whether combining a simple blood test (H. pylori serology) with a non-invasive abdominal ultrasound can accurately predict severe complications in patients with peptic ulcer disease (PUD). Peptic ulcer complications, such as stomach bleeding or perforation, are serious and typically require an invasive procedure called an upper endoscopy for diagnosis and treatment.\n\nResearchers want to find out if these two non-invasive tests can be used together to create a reliable risk-scoring system. This system would help doctors quickly identify which patients are at a high risk for complications and need an urgent endoscopy, compared to those who are at a lower risk and can be safely monitored without the invasive procedure.\n\nThe study will include adult patients presenting with stomach symptoms (like pain, nausea, or heartburn), as well as those with suspected or confirmed peptic ulcer disease. Participants will provide a blood sample to check for H. pylori antibodies and undergo a standard, painless abdominal ultrasound to examine the thickness of their stomach wall. An upper gastrointestinal endoscopy will be performed if it is clinically necessary as part of the patient's standard medical care.",[79,202,26,203,149],"HELICOBACTER PYLORI INFECTIONS","Peptic Ulcer",[205,206,207,79,26,208,149],"H. pylori serology","gastric ultrasound","peptic complications","Peptic Ulcer Complications","2026-03-04",{"date":211,"type":32},"2026-03-09",{"date":213,"type":22},"2026-04",{"date":215,"type":22},"2027-05",{"name":217,"class":39},"Assiut University",{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":74,"phases":228,"briefSummary":229,"conditions":230,"keywords":234,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":40},"100556749","h-pylori-eradication-with-argon-plasma-during-endoscopy-100556749","NCT06529159","H. Pylori Eradication With Argon Plasma During Endoscopy","H. Pylori Eradication With Argon Plasma During Endoscopy (HEAPE)","HEAPE","Inclusion Criteria:\n\n1. Subjects must be 18 years or older\n2. Confirmed untreated H. pylori infection\n3. Able to understand and sign informed consent\n4. Available to return for all routine follow-up study visits\n5. Patients should have upper endoscopy scheduled according to latest guidelines, e.g., as a part of their diagnostic work-up of HP positive test, regardless of their decision to participate in the study.\n\nExclusion Criteria:\n\n1. Patients actively undergoing H.pylori eradication therapy treatment with antibiotics or proton pump inhibitors (PPIs) two weeks prior to the HEAPE procedure.\n2. Pregnancy or puerperium\n3. Severe cardiopulmonary disease or a history of coronary artery disease (including myocardial infarction within the past 6 months, poorly controlled hypertension, required use of NSAIDs)\n4. Lactation\n5. An inability to provide informed consent\n6. Any other condition which the investigator may deem as an impediment to compliance or hinder completion of the proposed study.\n7. Hernias \u002F aspiration risk",{"count":227,"type":22},20,[104],"The objective of the study is to investigate the efficacy and safety of an argon plasma-based therapy - HEAPE - in treating H. pylori infections during endoscopic procedures. By filling the stomach with sodium chloride solution that is treated with APC (PAL), the Investigators hypothesize a significant reduction in H. pylori. The use of PAL instead of direct application of APC allows for a broader and more homogeneous application throughout the stomach and a faster procedure time, as the fluid bypasses the thermal effects typically associated with higher electrical power settings and focuses on the bactericidal action of PAL. It is a procedure that does not involve thermal ablation of the stomach lining. Thus, side effects should be expected to be as low as possible.\n\nTwo different PAL generation modalities will be compared in this study:\n\n1. HEAPE direct: This modality is the direct generation of PAL in the stomach. The stomach is filled with sodium chloride solution which is then treated with APC. With HEAPE direct a potential decrease of reactive species is avoided, as the treatment happens directly at the intended location in the H. pylori infected stomach.\n2. Pre-HEAPE: This modality features the treatment of sodium chloride with APC outside of the patient in a sterile container. After the APC treatment, the generated PAL is administered into the stomach with a syringe through the working channel of the endoscope. Pre-HEAPE allows an easier handling of the APC probe as the treatment of the sodium chloride solution can be done without an endoscope.\n\nTo evaluate the immediate effect of this novel treatment approach the metabolic activity of H. pylori will be assessed using a urea breath test (UBT) before and after treatment. A reduction in H. pylori levels can be detected by a reduction in urease activity in the breath test.\n\nAfter the HEAPE procedure, patients are treated with antibiotics (best practice) as they would be under normal circumstances. Four weeks after treatment, another UBT is performed to determine if H. pylori has been eradicated or if additional antibiotic treatment is indicated.\n\nThis two-arm, randomized, pilot, single-center, prospective clinical study is designed to evaluate the safety, tolerability and proof of concept that PAL has the ability to eradicate or reduce the bacterial load of H. pylori in humans.",[26,150,231,232,233],"Helicobacter Pylori Gastrointestinal Tract Infection","H. Pylori Infection","H. Pylori Gastrointestinal Disease",[235,236,237,238,239],"Urea Breath Test","Argon Plasma Coagulation (APC)","Endoscopy","Plasma Activated Liquid (PAL)","Plasma Medicine","2026-02-26",{"date":242,"type":32},"2026-03-02",{"date":244,"type":32},"2025-07-08",{"date":246,"type":22},"2027-12",{"name":248,"class":39},"Christopher C. Thompson, MD, MSc",{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":74,"phases":259,"briefSummary":260,"conditions":261,"keywords":262,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":269,"locationsCount":271},"100624135","phase-4-fecal-molecular-susceptibility-guided-hp-rescue-therapy-100624135","NCT07405697","Fecal Molecular Susceptibility-guided Hp Rescue Therapy","Clinical Efficacy and Health Economic Evaluation of Fecal Molecular Susceptibility-guided Therapy for Helicobacter Pylori Infection Rescue Treatment: Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n1. Voluntarily participate in this clinical study; fully understand, be informed about this study, and sign the Informed Consent Form (ICF).\n2. Age between 18 and 75 years (inclusive) on the day of signing the ICF.\n3. 13C-urea breath test (13C-UBT) and fecal HP nucleic acid detection confirming Helicobacter pylori (Hp) infection.\n4. previously eradicated HP\n\nExclusion Criteria:\n\n1. Individuals with a known allergy to the medication.\n2. Patients with severe cardiovascular, pulmonary, renal, hepatic, hematologic, neurologic, endocrine, or psychiatric disorders;\n3. Participants or guardians who refuse to enroll;\n4. Alcohol and\u002For drug abuse (dependence or addiction) or individuals judged by the physician to have poor compliance;\n5. Use of antibiotics, bismuth-containing drugs, PPIs, or traditional Chinese medicines within 4 weeks before treatment;\n6. Pregnant or lactating women;\n7. Any condition deemed by the investigator to be unsuitable for enrollment.","75 Years",{"count":258,"type":22},290,[76],"The goal of this clinical trial is to evaluate the eradication efficacy and health economic benefits of individualized regimens guided by fecal molecular susceptibility testing with 7-day and 14-day courses in the rescue treatment of Helicobacter pylori infection. The main questions it aims to answer are:\n\n1. What is the H. pylori eradication rate of the 7-day versus 14-day individualized regimens?\n2. What are the safety, adherence, and cost-effectiveness of the 7-day versus 14-day individualized regimens? Researchers will compare the 7-day course group and the 14-day course group to see if the 7-day course is non-inferior to the 14-day course in terms of eradication rate.\n\nParticipants will:\n\n1. Undergo fecal H. pylori drug resistance gene testing\n2. Receive randomized assignment to either 7-day or 14-day individualized treatment based on drug susceptibility results\n3. Complete follow-up visits at 1 week and 4-8 weeks after stopping treatment for adverse event monitoring and 13C-urea breath test",[26],[53],"2026-02-10",{"date":265,"type":32},"2026-02-12",{"date":267,"type":22},"2026-02-28",{"date":36,"type":22},{"name":270,"class":39},"Shanghai Zhongshan Hospital",4,{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":74,"phases":281,"briefSummary":282,"conditions":283,"keywords":284,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":291,"locationsCount":40},"100620477","efficacies-of-bismuth-amoxicillin-vonoprazan-triple-therapy-and-bismuth-quadruple-therapy-100620477","NCT07358130","Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy","Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy in the First-line Anti-Helicobacter Pylori Treatment","Inclusion Criteria:\n\n* Subjects with Helicobacter pylori infection\n\nExclusion Criteria:\n\n1. Subjects with known hypersensitivity to the study drug.\n2. Subjects with a history of gastric surgery.\n3. Subjects with severe liver cirrhosis or uremia.\n4. Subjects with a history of malignancy within the past five years.\n5. Pregnant or breastfeeding women.\n6. Subjects currently receiving treatment with atazanavir sulfate or rilpivirine hydrochloride.",{"count":280,"type":22},552,[104],"(1) To compare the efficacy and safety of a 14-day bismuth-amoxicillin-vonoprazan triple therapy versus a 14-day bismuth-based quadruple therapy as first-line treatments for H. pylori infection, and (2) To investigate the influence of H. pylori antibiotic resistance, along with host CYP3A4, CYP2C19, and IL-1B -511 genotypes, on the eradication efficacy of H. pylori therapies.",[26],[153],"2026-01-13",{"date":287,"type":32},"2026-01-22",{"date":289,"type":32},"2025-10-21",{"date":90,"type":22},{"name":292,"class":39},"Kaohsiung Medical University",{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":100,"enrollmentInfo":301,"targetDuration":303,"studyType":23,"phases":4,"briefSummary":304,"conditions":305,"keywords":306,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":40},"100614861","p-cabs-based-bismuth-quadruple-therapy-for-helicobacter-pylori-eradication-100614861","NCT07285096","P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication","Efficacy and Safety of P-CABs-Based Bismuth Quadruple Therapy for First-line Helicobacter Pylori Eradication: A Multicenter Cohort Study","PRO-HP","Inclusion Criteria:\n\n* patients aged 18-70 years, regardless of gender;\n* willing to receive H. pylori eradication therapy;\n* diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C\u002F¹⁴C-urea breath test, or histopathological examination.\n\nExclusion Criteria:\n\n* patients with incomplete medical records, including missing treatment details, absence of post-treatment follow-up test results, or failure to complete essential follow-up assessments;\n* patients who received treatment regimens that did not comply with the quadruple regimens specified in this study.",{"count":302,"type":22},1730,"8 Weeks","Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various potassium-competitive acid blockers (P-CABs) -based bismuth quadruple regimens and identify factors influencing treatment failure. A multicenter cohort study was conducted and study outcomes included eradication rates and incidence of adverse events.",[26],[53,307],"quadruple therapy","2025-12-20",{"date":310,"type":32},"2025-12-23",{"date":312,"type":32},"2025-12-16",{"date":314,"type":22},"2026-08-01",{"name":316,"class":39},"Yueyue Li",{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":122,"sex":17,"minAge":324,"maxAge":48,"enrollmentInfo":325,"targetDuration":4,"studyType":74,"phases":327,"briefSummary":328,"conditions":329,"keywords":330,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":342},"100510466","a-screen-and-treat-helicobacter-pylori-eradication-trial-in-adolescents-in-three-regions-of-chile-100510466","NCT05926804","A \"Screen and Treat\" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile","A Randomized \"Screen and Treat\" Helicobacter Pylori Eradication Trial in 14-18 Years Old Adolescents Residing in Three Regions of Chile: Effectiveness and Microbiological-host Implications","Inclusion Criteria:\n\n1. Healthy teenagers 14-18 years of age from Colina, Temuco or Coyhaique\n2. At least one responsible adult family member accessible for phone contact.\n3. Persistent H. pylori infection determined by at least 2 positive UBT tests in a 3 months period (except for Non-infected Controls)\n\nExclusion Criteria:\n\n1. Teenagers not consenting to treatment will be invited to continue as non-treated controls.\n2. Known allergy to any of the antimicrobials used in the trial protocol (except for Non-infected Controls)\n3. Signs\u002Fsymptoms compatible with organic abdominal pain according to Rome IV criteria: persistent right upper or right lower quadrant pain, dysphagia, odynophagia, persistent vomiting, gastrointestinal blood loss, involuntary weight loss, deceleration of linear growth, delayed puberty.\n4. Prior eradication therapy\n5. Antimicrobial course received during the previous month (at least 3 days of treatment at appropriate dosing, children meeting this criteria can be included at a later stage)\n6. Pregnancy\n7. Use of immunosuppressive or biologic drugs\n8. Children deemed \"not healthy\" after review of the questionnaire by study physician","14 Years",{"count":326,"type":22},500,[104],"Gastric cancer remains a global health problem, and Chile has one of the highest GC mortality rates in the region. Helicobacter pylori (H. pylori) infection is ubiquitous in Chilean adults, and it constitutes the main cause of GC worldwide. A long-term process occurs from premalignant lesions to carcinoma. H. pylori eradication during early stages of disease significantly impacts outcomes, favoring survival, disease reversal and molecular changes, which supports a \"screen and treat\" strategy in asymptomatic populations in areas with intermediate-to-high GC prevalence. The Investigators' previous research has shown that H. pylori infection is acquired in early childhood with low rates of spontaneous eradication. A pilot treatment study in a subset of school-aged asymptomatic children showed a high rate of successful eradication (\\>95%), good tolerance, and was associated with a decrease in serum biomarkers of gastric damage (pepsinogen I and II). Based on the results of these studies, the Investigators propose to advance towards the next stage of this research process: a \"screen and treat\" strategy. The current trial starts with a Screening phase testing up to 1000 asymptomatic adolescents 14-18 years of age from 3 cities of Chile (Colina, Temuco and Coyhaique), to find a total of 210 persistently-infected participants. Persistently-infected adolescents will be included in a Second phase of this trial: A randomized, case-control, non-blinded study to either receive antimicrobial treatment targeting H. pylori eradication (cases) or no treatment (controls). A subset of 60 non-infected adolescents will be followed-up in matched times. This aims to provide evidence on the effect of treatment on clinical outcomes and serum biomarkers related to gastric damage, as well as composition and antimicrobial resistance of gut microbiota. The Investigators expect that eradication therapy will be successful in \\>90% of persistently infected adolescents, with reinfection rates not surpassing 15% in a 2-3 year period, and to be associated with a decrease in clinical findings indicative of gastric disease, and a decrease in serum biomarker indicative of \"gastric damage\".",[26],[53,331,332,333],"Screen and treat","Pepsinogen","Adolescent",{"date":335,"type":32},"2025-12-17",{"date":337,"type":32},"2022-08-02",{"date":339,"type":22},"2027-08",{"name":341,"class":39},"Miguel O'Ryan Gallardo",3,{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":17,"minAge":350,"maxAge":351,"enrollmentInfo":352,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":354,"conditions":355,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":40},"100377209","the-gastric-precancerous-conditions-study-100377209","NCT04191551","The GAstric Precancerous Conditions Study","GAPS","Inclusion Criteria: Subjects between the ages of 35 and 84, who are undergoing outpatient endoscopy for the following indications are eligible: abdominal pain, dyspepsia, iron deficiency anemia, Helicobacter assessment, surveillance of suspected or known intestinal metaplasia, evaluation for family history of gastric cancer\n\nExclusion Criteria:\n\n* Cannot give consent\n* Have history of gastric surgery\n* Have history of solid tumor or bone marrow transplant\n* Platelet Count \\\u003C 70 or international normalized ratio \\> 1.5","35 Years","84 Years",{"count":353,"type":22},600,"Gastric cancer afflicts 27,000 Americans annually and carries a dismal prognosis. One reason for poor outcomes is late diagnosis, as the majority of gastric cancers in the United States are diagnosed at a relatively advanced stage where curative resection is unlikely. Gastric precursors (such as atrophic gastritis and intestinal metaplasia) are precancerous changes to the stomach mucosa which increases risk for subsequent gastric cancer.\n\nThe Gastric Precancerous Conditions Study (GAPS) is an observational study of patients at elevated risk for gastric cancer. Investigators seek to recruit patients from endoscopy unit of Stanford Health Care, a large academic network of hospitals and clinics serving Northern California. Investigators will recruit patients who are both symptomatic (e.g. dyspepsia) and asymptomatic (e.g. referred for screening), and individuals both with known precursor lesions (such as intestinal metaplasia) or at high risk for carrying precursor lesions. A component of the study is long-term follow-up of individuals with gastric precursors. This is to understand their risk factors for histologic progression and regression. During both index and subsequent endoscopies, the study team will collect biospecimens (e.g. blood, saliva, gastric tissue).",[356,357,26,358],"Gastric Cancer","Intestinal Metaplasia of Gastric Mucosa","Atrophic Gastritis","2025-12-13",{"date":312,"type":32},{"date":362,"type":32},"2018-07-30",{"date":364,"type":22},"2028-06-30",{"name":366,"class":39},"Stanford University",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":122,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":383,"leadSponsor":385,"locationsCount":4},"100613906","effect-of-h-pylori-eradication-on-the-improvement-of-gastrointestinal-symptoms-100613906","NCT07272681","Effect of H. Pylori Eradication on The Improvement of Gastrointestinal Symptoms","Effect of Helicobacter Pylori Eradication on Gastrointestinal Symptoms in Adult Patients","HPE-GI","Inclusion Criteria:\n\n1. Adults aged 18 years and older.\n2. Confirmed diagnosis of Helicobacter pylori infection by one or more diagnostic tests.\n3. Presence of any upper or lower gastrointestinal symptoms.\n4. Willingness to undergo H. Pylori eradication therapy and follow-up.\n5. Ability to provide informed consent.\n\nExclusion Criteria:\n\n1. Age less than 18 years.\n2. The previously unsuccessful application of empirical H. pylori eradication therapy.\n3. Use of non-steroidal anti-inflammatory drugs (NSAIDs).\n4. Any malignant disease of the stomach or any other site.\n5. Any associated comorbidity (renal insufficiency, mental illness).\n6. History of allergies to proton pump inhibitors or antibiotics.\n7. Refusal to participate in the survey.",{"count":376,"type":22},100,"This study aims to evaluate the effect of Helicobacter pylori eradication on gastrointestinal symptoms in adult patients. H. pylori infection is a common cause of dyspepsia and other upper gastrointestinal complaints. The trial will assess whether successful eradication therapy leads to significant improvement in symptoms compared to baseline. Adult patients diagnosed with H. pylori infection will receive standard eradication treatment, and symptom changes will be monitored using validated questionnaires over a defined follow-up period.",[26,149,379],"Gastrointestinal Symptoms","2025-12-08",{"date":312,"type":32},{"date":308,"type":22},{"date":384,"type":22},"2026-12-20",{"name":386,"class":39},"Amany Usama Ahmed Arafa",{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":256,"enrollmentInfo":394,"targetDuration":4,"studyType":74,"phases":396,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":40},"100603657","phase-4-saccharomyces-boulardii-combined-with-bismuth-quadruple-therapy-for-helicobacter-pylori-rescue-treatment-100603657","NCT07139366","Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment","Efficacy and Safety of Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment: A Prospective, Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18\\~75, both gender.\n* Patients who had failed H.pylori eradication therapies .\n* Women are eligible if they are not pregnant or nursing, and if they are of childbearing potential they are required to use medically acceptable contraception for the duration of the study and 30 days thereafter.\n\nExclusion Criteria:\n\n* Patients who have previously used tetracycline and furazolidone antibiotics to eradicate infection with H. pylori.\n* Contraindications to study drugs.\n* Substantial organ impairment, severe or unstable cardiopulmonary or endocrine disease.\n* Constant use of anti-ulcer drugs ( including taking proton-pump.inhibitors(PPI) within 2 weeks before the \\[13C\\] urea breath test), antibiotics or bismuth complexes (more than 3 times \u002F1 month before screening).\n* Pregnant or lactating women.\n* Underwent upper gastrointestinal Surgery.\n* Dysphagia.\n* Evidence of bleeding or iron efficiency anemia.\n* A history of malignancy.\n* Drug or alcohol abuse history in the past 1 year.\n* Systemic use of corticosteroids, non steroidal anti-inflammatory drugs, anticoagulants, platelet aggregation inhibitors (except the use of aspirin for less than 100 mg\u002Fd).\n* Mental disorder.\n* Enrolled in other clinical trials in the past 3 months.\n* Refuse to sign informed consent.",{"count":395,"type":22},1248,[76],"This study aims at evaluating efficacy and safety of Saccharomyces boulardii combined with bismuth-containing quadruple Therapy versus bismuth-containing quadruple Therapy(bismuth#esomeprazole#tetracycline and furazolidone) in H. pylori rescue therapy. It is hypothesized that Saccharomyces boulardii combined with bismuth-containing quadruple Therapy is superior to bismuth-containing quadruple Therapy. Patients with confirmed failure of H. pylori eradication will be randomized to one of the treatments described above. At week 6 follow-up visits, a urea breath test#rapid urease test or helicobacter pylori stool antigen test will be performed to confirm eradication.",[80,149,26,356,203],"2025-11-30",{"date":401,"type":32},"2025-12-02",{"date":403,"type":32},"2025-10-28",{"date":405,"type":22},"2026-09",{"name":407,"class":39},"Yongquan Shi",{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":17,"minAge":415,"maxAge":416,"enrollmentInfo":417,"targetDuration":4,"studyType":74,"phases":418,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":40},"100612932","treatment-efficacy-of-regimens-with-and-without-bismuth-in-children-with-helicobacter-pylori-associated-peptic-ulcer-disease-100612932","NCT07260006","Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease","A Study on the Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease","Inclusion Criteria:\n\n* Diagnosed with gastritis or peptic ulcer disease by upper gastrointestinal endoscopy or histopathology.\n* Meets diagnostic criteria for Helicobacter pylori infection.\n* Parent or legal guardian provides consent for the child to participate in the study.\n\nExclusion Criteria:\n\n* Allergic to any of the medications in the treatment regimen.\n* Use of antibiotics or bismuth within the past 4 weeks, or use of antacids, H2-receptor antagonists, or proton pump inhibitors within the past 2 weeks.\n* Failure to return for follow-up visits after treatment.","5 Years","15 Years",{"count":145,"type":22},[104],"The goal of this clinical trial is to learn if including bismuth in the treatment helps heal stomach and duodenal ulcers caused by Helicobacter pylori (H. pylori) in children.\n\nThe main questions it aims to answer are:\n\n* Does a treatment plan with bismuth work better than a plan without bismuth to clear the infection?\n* Is the bismuth plan more cost-effective while still safe and effective?\n\nResearchers will compare two treatment groups to see which works better. Participants will:\n\n* Take one of the two assigned treatment plans (with or without bismuth) for the standard treatment duration\n* Visit the clinic for checkups and tests to confirm infection clearance and monitor side effects\n* Keep a diary of symptoms, medication use, and any side effects",[26,203],"2025-11-21",{"date":401,"type":32},{"date":424,"type":32},"2024-10-01",{"date":426,"type":22},"2026-05-30",{"name":428,"class":39},"Can Tho University of Medicine and Pharmacy",{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":100,"enrollmentInfo":437,"targetDuration":4,"studyType":74,"phases":439,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":40},"100611582","phase-2-head-to-head-study-of-tegoprazan-50-mg-bid-plus-amoxicillin-1-g-tid-vs-vonoprazan-20-mg-bid-plus-amoxicillin-1-g-tid-for-h-pylori-eradication-100611582","NCT07242456","Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication","Head-to-head Comparison of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID Versus Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for Helicobacter Pylori Eradication: A Randomized, Open-label, Parallel-group Study","TV-HP","Inclusion Criteria:\n\n* 1\\. Adults aged 18 to 70 years. 2. Confirmed Helicobacter pylori infection based on at least one positive test (13C-urea breath test, rapid urease test, histology, or stool antigen test). 3. Able and willing to provide written informed consent. 4. Able to comply with study procedures and visits. 5. For females of childbearing potential: agreement to use effective contraception during the study period.\n\nExclusion Criteria:\n\n* 1\\. Previous Helicobacter pylori eradication therapy within the past 12 months. 2. Use of antibiotics, bismuth compounds, or other medications with anti-H. pylori activity within 4 weeks before baseline testing. 3. Use of proton pump inhibitors, P-CABs, or H2-receptor antagonists within 2 weeks before baseline testing. 4. Known allergy or intolerance to tegoprazan, vonoprazan, amoxicillin, or any beta-lactam antibiotic. 5. Known severe hepatic impairment (e.g., Child-Pugh C) or severe renal impairment (e.g., eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²). 6. History of gastric surgery (except minor endoscopic procedures that do not affect gastric anatomy).\n\n  7\\. Active gastrointestinal bleeding or suspected gastric malignancy. 8. Pregnant or breastfeeding women. 9. Participation in another interventional clinical trial within the past 30 days.\n\n  10\\. Any medical or psychiatric condition that, in the investigator's judgment, could interfere with study participation or pose unacceptable risk.",{"count":438,"type":22},240,[440,441],"PHASE2","PHASE3","This study is a randomized, open-label, parallel-group clinical trial designed to compare two 14-day dual therapies for the eradication of Helicobacter pylori (H. pylori) infection. Participants will be randomly assigned to receive either tegoprazan 50 mg twice daily plus amoxicillin 1 g three times daily, or vonoprazan 20 mg twice daily plus amoxicillin 1 g three times daily.\n\nThe primary purpose of this study is to evaluate whether the tegoprazan-based regimen is non-inferior to the vonoprazan-based regimen in terms of H. pylori eradication rates. Eradication will be assessed 4 to 8 weeks after completing therapy using a \\^13C-urea breath test. Secondary objectives include assessing treatment-related adverse events, tolerability, and medication adherence.\n\nThis study involves adult participants with confirmed H. pylori infection. All study medications are orally administered, and both regimens use drugs with well-established safety profiles. The study is investigator-initiated and conducted at Hangzhou First People's Hospital.",[26],"2025-11-17",{"date":421,"type":32},{"date":447,"type":32},"2025-02-17",{"date":449,"type":22},"2026-01-31",{"name":451,"class":39},"First People's Hospital of Hangzhou",{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":74,"phases":461,"briefSummary":462,"conditions":463,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":472,"leadSponsor":474,"locationsCount":40},"100605663","potassium-competitive-acid-blocker-versus-proton-pump-inhibitor-as-a-part-of-bismuth-based-quadruple-therapy-for-treatment-of-helicobacter-pylori-infection-100605663","NCT07165444","Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection","Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Both sexes.\n* Confirmed Helicobacter pylori infection by stool antigen (3rd-gen ELISA) or urea breath test (UBT).\n* No prior eradication therapy.\n\nExclusion Criteria:\n\n* Prior Helicobacter pylori treatment.\n* Use of antibiotics, proton pump inhibitor, or bismuth in the prior 4 weeks.\n* Gastric surgery history.\n* Major organ failure.\n* Pregnancy or lactation.\n* Known allergy to study drugs.",{"count":460,"type":22},320,[104],"This study aims to compare the eradication rate, safety, and patient adherence between potassium-competitive acid blockers (P-CABs) and proton pump inhibitor-based bismuth quadruple therapy in patients with Helicobacter pylori infection.",[464,465,466,467,26],"Potassium-Competitive Acid Blocker","Proton Pump Inhibitor","Bismuth Based Quadruple Therapy","Treatment","2025-09-11",{"date":470,"type":32},"2025-09-12",{"date":468,"type":32},{"date":473,"type":22},"2026-02-01",{"name":475,"class":39},"Tanta University",{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":74,"phases":485,"briefSummary":486,"conditions":487,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":495,"locationsCount":497},"100418423","phase-4-the-effect-of-dual-eradication-therapy-vs-ppi-on-gastrointestinal-bleeding-in-acs-patients-100418423","NCT04728516","The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients","The Effect of Vonoprazan-based Dual Eradication Therapy vs PPI Treatment on Gastrointestinal Bleeding in ACS Patients With Hp Infection and Coronary Stents: an Open-label, Randomized, Controlled Trial","Inclusion Criteria:\n\n1. Patients with ACS and PCI treatment and postoperative DAPT ≥ 6 months;\n2. Hp infection is positive;\n3. Age ≥18 years old;\n4. The patient himself or his authorized client signs the subject's consent.\n\nExclusion Criteria:\n\n1. Previous history of gastrointestinal ulcer bleeding;\n2. Long-term use of PPI and H2 receptor inhibitors in the past;\n3. Complicated with gastroesophageal varices, or after gastrectomy;\n4. Those who are taking anti-coagulation drugs such as vitamin K antagonists (warfarin) ,factor X or factor II inhibitors;\n5. Recently received fibrinolytic therapy (using fibrin-specific drugs within 24 hours before randomization, or using non-fibrin-specific drugs within 48 hours before randomization);\n6. Recently accepted (within 30 days before randomization) or planned to undergo coronary artery bypass grafting (CABG);\n7. Combining active bleeding or coagulation dysfunction (indicator);\n8. In patients with liver and kidney disease, serum creatinine is greater than 150 μmol\u002FL, GFR \\\u003C60ml\u002Fmin\u002F1.73m2, alanine aminotransferase and aspartate aminotransferase increase ≥3 times from the normal value;\n9. Complicated with hemorrhagic stroke, intracranial tumor, arteriovenous malformation or aneurysm;\n10. Anemia (adult male hemoglobin less than 120 g\u002FL or red blood cells less than 4×10\\^12\u002FL,adult female hemoglobin less than 105 g\u002FL or red blood cells less than 3.5×10\\^12\u002FL);\n11. Systemic glucocorticoid application;\n12. Have taken antibiotics and other drugs that affect the flora in the stomach within the past month;\n13. A history of allergy to aspirin, clopidogrel, ticagrelor, pantoprazole, penicillin and other test drugs;\n14. Pregnancy or breastfeeding women and subjects of childbearing age who do not want to take contraceptive measures;\n15. With malignant tumors and other diseases, the expected survival time is less than 1 year;\n16. Patients who participated in clinical trials of other drugs or are participating in clinical studies of other new drugs within 30 days before enrollment;\n17. Complicated with mental illness or severe neurosis;\n18. Can't express subjective discomfort symptoms;\n19. The investigator decides that it is not suitable to participate in this research.",{"count":484,"type":22},2600,[76],"Patients with acute coronary syndrome (ACS) after Percutaneous Coronary Intervention (PCI) require routine treatment with dual antiplatelet (DAPT) treatment, but with the high risk of bleeding, gastrointestinal bleeding is the most common type of major bleeding. Helicobacter pylori (Hp) infection is a high-risk factor for gastrointestinal bleeding, with an incidence of about 50%. Foreign authoritative DAPT guidelines do not give individual guidance to Hp-infected patients. It is recommended that those with high bleeding risk should be combined with proton pump inhibitors (PPI), but long-term compliance with PPI is not ideal. Authoritative experts in China have agreed to recommend Hp detection and eradication therapy for DAPT patients, but loss of evidence. Vonoprazan is a novel potassium ion competitive acid blocker, based on Vonoprazan's dual Hp eradication therapy is simple and effective. Our team will conduct a multi-center, open-label, randomized controlled clinical trial using a non-inferior design to compare the combination of Vonoprazan + amoxicillin combined with pantoprazole (PPI) for 6 months after PCI on the bleeding events of the digestive tract.",[488,26],"Acute Coronary Syndrome","2025-09-09",{"date":491,"type":32},"2025-09-16",{"date":493,"type":32},"2023-04-12",{"date":62,"type":22},{"name":496,"class":39},"Qilu Hospital of Shandong University",42,{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":505,"enrollmentInfo":506,"targetDuration":4,"studyType":74,"phases":508,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":4},"100605199","huazhi-rougan-granule-as-an-add-on-therapy-for-h-pylori-infection-with-metabolic-associated-steatohepatitis-100605199","NCT07159412","Huazhi Rougan Granule as an Add-On Therapy for H. Pylori Infection With Metabolic-associated Steatohepatitis","A Randomized, Double-Blind, Placebo-Controlled Trial of Huazhi Rougan Granule Combined With High-Dose Dual Therapy for Helicobacter Pylori Infection Complicated With Metabolic-associated Steatohepatitis (Dampness-Heat Accumulation Syndrome)","Inclusion Criteria:\n\n1. Aged 18-65 years;\n2. Meeting the diagnostic criteria for metabolic-associated steatohepatitis (MASH) and the traditional Chinese medicine syndrome differentiation criteria for dampness-heat accumulation pattern;\n3. Initial treatment for H. pylori infection (positive 13C- or 14C-urea breath test);\n4. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Individuals with fatty liver caused by chronic heart failure, malnutrition, or pregnancy; those with fatty liver syndrome in encephalopathy, abetalipoproteinemia, or localized fatty liver;\n2. Patients with severe fatty liver accompanied by ascites, edema, hyponatremia, hypokalemia, or other signs suggestive of cirrhosis; those with hepatitis or cirrhosis caused by viruses, drug toxicity, autoimmune diseases, or other factors;\n3. Individuals using hepatoprotective, enzyme-lowering, or lipid-lowering medications that may interfere with efficacy evaluation;\n4. Pregnant or lactating women;\n5. Patients with severe primary cardiovascular, renal, or other life-threatening diseases;\n6. Individuals with a history of cancer;\n7. Those positive for HCV antibody, HIV antibody, or HBsAg with detectable HBV-DNA levels;\n8. Individuals with a history of alcohol abuse (≥210 g\u002Fweek for males or ≥140 g\u002Fweek for females) or substance abuse;\n9. Those with known hypersensitivity to any component of the study drug;\n10. Participation in another clinical trial within 3 months prior to screening;\n11. Use of Chinese herbal medicines for the treatment of non-alcoholic simple fatty liver within 2 weeks prior to screening;\n12. Individuals deemed unsuitable for participation by the investigator.","65 Years",{"count":507,"type":22},286,[104],"This study employed a double-blind, randomized, placebo-controlled design. Eligible treatment-naïve patients with Helicobacter pylori (Hp) infection complicated by metabolic-associated steatohepatitis (MASH) (dampness-heat accumulation syndrome) were enrolled and randomly assigned to either the experimental group or the placebo control group. Both groups received a 2-week Hp eradication regimen consisting of vonoprazan (20 mg twice daily) and amoxicillin (1000 mg three times daily). The experimental group additionally received active Huazhi Rougan Granule (taken orally three times daily, one sachet each time, with a 6-day medication followed by a 1-day drug holiday per cycle), while the placebo control group received an identical matching placebo on the same schedule. The study aims to evaluate the synergistic therapeutic efficacy of Huazhi Rougan Granule in combination with the vonoprazan-amoxicillin dual therapy.",[26,511,512,513],"Metabolic-associated Steatohepatitis","High-dose Dual Therapy","Huazhi Rougan Granule","2025-09-05",{"date":516,"type":32},"2025-09-08",{"date":518,"type":22},"2025-08-31",{"date":520,"type":22},"2027-08-31",{"name":522,"class":39},"Nanjing First Hospital, Nanjing Medical University",{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":530,"enrollmentInfo":531,"targetDuration":4,"studyType":74,"phases":533,"briefSummary":534,"conditions":535,"keywords":536,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":544,"locationsCount":40},"100388059","phase-4-susceptibility-testing-guided-versus-empirical-therapy-for-refractory-h-pylori-infection-100388059","NCT04332848","Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection","Comparison of Susceptibility Testing Guided Versus Empirical Therapy for the Third-line Eradication of H. Pylori- a Multicenter Randomized Trial","Inclusion criteria\n\n* Adult (equal or greater than 20 years old) patients who failed from at least two eradication therapies for H. pylori infection will be enrolled.","90 Years",{"count":532,"type":22},360,[76],"Aim: Therefore, we aimed to\n\n1. compare the efficacy of susceptibility testing guided therapy vs. empirical therapy in the third-line eradication for refractory H. pylori infection\n2. assess the long-term impact of eradication therapy on the antibiotic resistance and microbiota of the gut flora and the metabolic factors.\n\nMethods: This will be a multi-center, open labeled trial\n\nPatients: 360 patients with failure to H. pylori eradication for at least two times will be enrolled Determination of antibiotic resistance of H. pylori:\n\nAgar dilution test will be used to determine the minimum inhibitory concentrations of levofloxacin, tetracycline, rifabutin, and clarithromycin to guide the selection of antibiotics.\n\nTreatment regimens and assignment: Eligible patients will be randomized to receive either one of the treatments (A) Susceptibility testing guided therapy or (B) Empirical therapy\n\nOutcome Measurement:\n\nPrimary End Point: Eradication rate will be evaluated according to Intent-to-treat (ITT) analyses.\n\nSecondary End Point: 1. Eradication rate according to per protocol analysis (PP analysis); 2. Frequency of adverse effects.",[26],[537],"Helicobacter pylori,Susceptibility testing,empirical,third-line treatment","2025-08-24",{"date":540,"type":32},"2025-08-29",{"date":542,"type":32},"2020-07-28",{"date":189,"type":22},{"name":38,"class":39},{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":17,"minAge":552,"maxAge":530,"enrollmentInfo":553,"targetDuration":4,"studyType":74,"phases":555,"briefSummary":556,"conditions":557,"keywords":558,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":4},"100594613","phase-4-comparison-of-two-treatment-regimens-of-helicobacter-pylori-infection-100594613","NCT07021729","Comparison of Two Treatment Regimens of Helicobacter Pylori Infection","Comparison of Conventional Clarithromycin Vs Alternative Levofloxacin Based Regimen in Treatment of Helicobacter Pylori Infection","Inclusion Criteria:\n\n* All patients who tested positive on stool antigen will be included.\n\nExclusion Criteria:\n\n* patients under 12 years old. Patients who have penicillin allergy.\n* Patients who have underlying dysrhythmia forbidding the use of macrolide.\n* Patient who have hypersensitivity to any of these antibiotics.","12 Years",{"count":554,"type":22},156,[76],"The goal of this interventional study is to compare the efficacy of clarithromycin Vs levofloxacin based regimen in treatment of Helicobacter pylori infection in patients presenting to medical OPD who are tested positive for H pylori infection.. The main question\\[s\\] it aims to answer are:\n\n• Which regimen is superior in terms of efficacy Participants will be treated for H pylori Infection in with two different regimen If there is a comparison group: Researchers will compare two groups Group 1 will receive clarithromycin based regimen group 2 will receive levofloxacin based regimen to see the treatment response.",[26],[559,560,561],"clarithromycin","levofloxacin","helicobacter pylori","2025-06-11",{"date":564,"type":32},"2025-06-15",{"date":566,"type":22},"2025-12",{"date":568,"type":22},"2026-06",{"name":570,"class":39},"Rehman Medical Institute - RMI",{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":19,"enrollmentInfo":578,"targetDuration":4,"studyType":74,"phases":580,"briefSummary":581,"conditions":582,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":40},"100589819","phase-4-vonoprazan-evaluation-compared-to-standard-triple-therapy-in-helicobacter-pylori-eradication-100589819","NCT06959368","Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication","A Randomised Controlled Trial Comparing Vonoprazan Triple Therapy (Vonoprazan, Amoxicillin, Clarithromycin), and Standard Triple Therapy (Esomeprazole, Amoxicillin, Clarithromycin) for Helicobacter Pylori Eradication in Indian Population. VECTOR Trial - Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication","Inclusion Criteria:\n\n* Adult (18 years - 80 years)\n* Patient visiting clinic with dyspepsia, GERD, or non-bleeding peptic ulcer\n* 13C-urea breath test (UBT) positive\u002F Rapid urease test positive (RUT) on endoscopic biopsy\n* Off PPIs for 2 weeks\n\nExclusion Criteria:\n\n* Penicillin allergy\n* Recent use of antibiotics in the past 1 month\n* Previous H. pylori therapy\n* Intestinal metaplasia, gastric cancer, bleeding peptic ulcer\n* Patient who is unable to understand study protocol or not consenting\n* Pregnancy, lactation\n* Patient on anticoagulation, NSAIDs\n* Patient using drugs with interactions with vonoprazan, amoxicillin, clarithromycin or PPIs\n* Cirrhosis, Chronic kidney disease, chronic lung disease",{"count":579,"type":22},484,[76],"Helicobacter pylori (H Pylori) infection is associated with functional dyspepsia, peptic ulcer disease, atrophy and gastric cancer. The bacterium has been classified as grade I carcinogen by the WHO in 1994(1). Based on the clinical and microbiological data it is now well known to be the strongest risk factor for developing intestinal type and diffuse type of adenocarcinoma(2-4). While testing and treating asymptomatic persons is a grey area, it is now recommended to rule out H. pylori in un-investigated dyspepsia patients (5-7), and if detected, it must be treated. However, worldwide and especially in the Asian countries, we face a widespread problem of antibiotic resistance(8,9). Regimens are typically selected based on the varying regional clarithromycin resistance(6,9). There is a need for an efficient and reliable empirical therapy that can be universal, has maximal eradication rates irrespective of resistance patterns, has good compliance and minimal adverse events without the emergence of superbugs. We also need a reliable rescue therapy for H. pylori eradication failure.",[26],"2025-06-06",{"date":562,"type":32},{"date":586,"type":32},"2025-03-25",{"date":588,"type":22},"2026-03-25",{"name":590,"class":39},"Asian Institute of Gastroenterology, India",{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":4,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":598,"minAge":416,"maxAge":599,"enrollmentInfo":600,"targetDuration":602,"studyType":23,"phases":4,"briefSummary":603,"conditions":604,"keywords":608,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":40},"100566835","a-study-of-the-safety-of-vonoprazan-exposure-in-pregnant-women-and-their-offspring-100566835","NCT06660342","A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring","Vonoprazan Pregnancy Registry: An Observational Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring","Inclusion Criteria:\n\n* Women 15 to 50 years of age.\n* Currently or recently pregnant.\n* Consent to participate.\n* Authorization for her health care provider(s) (HCP\\[s\\]) to provide data to the registry.\n* Exposed cohort: Exposure to at least one dose of vonoprazan during pregnancy.\n* Unexposed cohort: Unexposed to vonoprazan and diagnosis of any condition for which vonoprazan may be prescribed.\n\nExclusion Criteria:\n\n* Occurrence of pregnancy outcome prior to first contact with the virtual research coordination center (VRCC) (retrospectively enrolled).\n* Exposure to known tetratogens and\u002For investigational medications during pregnancy.\n* Lost to follow-up.","FEMALE","50 Years",{"count":601,"type":22},728,"12 Months","The main objective of the study is to compare the maternal, fetal, and infant outcomes of pregnant women who are exposed to vonoprazan during pregnancy with outcomes of an internal comparison cohort of pregnant women who are unexposed to vonoprazan during pregnancy but who may be exposed to other products for the treatment of conditions for which vonoprazan may be prescribed.",[605,606,607,26],"Erosive Esophagitis","Heartburn","Symptomatic Non-erosive Gastroesophageal Reflux Disease",[605,606,607,26,609,610,611],"Pregnant Women","Fetal","Infant","2025-05-21",{"date":614,"type":32},"2025-05-22",{"date":616,"type":32},"2025-05-15",{"date":618,"type":22},"2034-09",{"name":620,"class":621},"Phathom Pharmaceuticals, Inc.","INDUSTRY"]